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Abstract
In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential
thrombocythemia (ET, n= 48), polycythemia vera (PV, n= 42), myelofibrosis (MF, n= 56), and prefibrotic myelofibrosis
(pre-PMF, n= 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one,
were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence
of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were
seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in
the pre-COVID last follow-up.This decline was remarkably higher in ET (−23.3%, p < 0.0001) than in PV (−16.4%, p=
0.1730) and was associated with higher mortality rate (p= 0.0010) for pneumonia. The effects of possible predictors of
thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a
multivariate model. Independent risk factors were transfer to ICU (SHR= 3.73, p= 0.029), neutrophil/lymphocyte ratio
(SHR= 1.1, p= 0.001) and ET phenotype (SHR= 4.37, p= 0.006). The enhanced susceptibility to ET-associated VTE and
the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be
delved to tailor new antithrombotic regimens including antiplatelet drugs.
Introduction
Coronavirus-2 (SARS-CoV-2) infection, when present-
ing as coronavirus disease 2019 (COVID-19), mainly
affects the respiratory system. However, multiple organ
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damage, involving the brain, heart, kidney, and vascular
system are being reported with increasing frequency, and
contribute to the high mortality rate. COVID-19 is
characterized by the occurrence of venous thromboem-
bolism (VTE) and/or arterial thrombosis, as well as
occlusions in the microcirculation, leading to severe
morbidity and mortality1–3. A possible mechanism of this
systemic damage may be that coronavirus attacks the
human body through the angiotensin-converting enzyme
2 (ACE2), which is distributed over blood vessels and in
various organs4,5.
The incidence rate of thromboembolic events is variable
and largely depends on whether patients were specifically
screened for the presence of thrombosis and hospitalized
in the intensive care unit (ICU) rather than in regular
wards6. In hospitalized COVID-19 patients, the overall
incidence of these events was estimated 22.7% in patients
transferred to ICU and 7.9% in general wards6. On the
basis of autopsy findings, extensive thrombosis of pul-
monary microvascular circulation has been consistently
documented7 and the concept of “in situ” pulmonary
thrombosis associated with respiratory worsening and
eventually death, was proposed8,9.
VTE and arterial thrombosis may be a major concern in
some categories of patients with SARS-CoV-2 infection,
such as the ones with generic cardiovascular risk factors,
including hypertension, obesity, diabetes, or cardiovas-
cular and chronic respiratory disease, and cancer. Patients
with myeloproliferative neoplasms (MPN), who are con-
stitutively prone to develop thrombotic complications,
might be amongst the most vulnerable to these events.
Patients with essential thrombocythemia (ET), poly-
cythemia vera (PV), and myelofibrosis (MF) suffer from a
2–4-fold higher incidence of arterial and venous throm-
bosis than the general population10,11, and also the fre-
quency of spontaneous or drug-related bleeding is also
higher than in general population12. Therefore, knowing
whether the rate of thrombotic and hemorrhagic events in
the course of COVID-19 is higher in these patients than in
the general COVID-19 population and identifying asso-
ciated risk factors, could be of great benefit in indivi-
dualizing prophylaxis and antithrombotic therapy.
Based on these premises and given that the prevalence
of MPN is relatively low13,14, we launched an international
multicenter study collecting data in ET, PV, and MF
patients with COVID-19, recruited in specialized hema-
tology European centers, during the first wave of the
pandemic. The primary goal was to evaluate the incidence
of thrombosis and bleeding and to identify associated
predictors.
Subjects and methods
MPN-COVID (ClinicalTrials.gov identifier: NCT04385160)
is a multicenter, retrospective, cohort study that involved 38
hematology units in Europe, on behalf of European Leuke-
miaNet (ELN) and with the endorsement of the European
Hematology Association (EHA) and GEMFIN Spanish
network.
The sponsor of the study is FROM—Fondazione per la
Ricerca Ospedale di Bergamo at Papa Giovanni XXIII
hospital in Bergamo (Italy), which obtained national
approval for conducting the study in Italy by the ethical
committee of the Spallanzani Hospital (approval number:
77-2020), in Rome (Italy); all other participating centers
got the approval by their respective local ethical com-
mittees and institutional review boards.
Eligible patients were consecutive adults (aged ≥ 18
years) with WHO-2016 diagnosis of MPN and SARS
CoV-2 infection detected between February 15 and May
31, 2020. The minimum follow-up time was 1 month; the
study was closed on June 30, 2020. An amendment to the
original protocol (version no. 2, 25/06/2020) has been
approved to extend the follow-up study period by an
additional 6 months after the last study visit for survivors.
Inclusion criteria included hospitalized COVID-19
cases ascertained by a positive real-time reverse tran-
scriptase polymerase chain reaction from nasopharyngeal
swab; however, given the exceptional situation of emer-
gency determined by pandemic crisis, also home-treated
patients unable to swab were included, when the presence
of pneumonia and symptoms were highly suggestive for
SARS CoV-2 infection (i.e., fever, cough, oxygen satura-
tion (O2 saturation) ≤ 93% at rest, dyspnea, diarrhea). For
the purposes of this analysis, only patients with non-
missing information regarding assessment of thrombosis
were included.
Written informed consent of participants was collected
whenever possible according to each Country regulation.
Data collection was centralized at FROM and per-
formed through a dedicated Electronic Data Capture
(EDC) system supporting electronic case report forms (e-
CRFs) set up on purpose. Data on demographic and
clinical characteristics, laboratory parameters, and drug
exposure were collected at relevant time points, namely (i)
last MPN follow-up visit before COVID-19 onset; (ii)
COVID-19 diagnosis; (iii) MPN follow-up after COVID-
19; and (iv) last visit.
All nasopharyngeal swabs for COVID-19 diagnosis were
managed according to national recommendations and
COVID-19 disease was assessed according to current
WHO guidance15. Respiratory disease severity at COVID-
19 diagnosis was categorized based on oxygen support
needs, as non-intensive (including low-flow oxygen,
Venturi mask, non-rebreather masks, continuous positive
airway pressure [CPAP], non-invasive ventilation [NIV])
and intensive (whether in need of either endotracheal
intubation, or invasive mechanical ventilation, or extra
corporeal membrane oxygenation [ECMO]).
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The primary outcome was the incidence of pulmonary
embolism (PE) with or without deep vein thrombosis
(DVT) of the legs, which had to be confirmed by imaging
(ultrasounds and computed tomography [CT] angio-
graphy). Presumed PEs were cases unable to be confirmed
by imaging due to the practical limitations imposed by the
severity of infection and were also registered if they were
defined by sudden increase of either D-Dimer in patients
with rapid worsening of respiration and/or increase of
oxygen need.
Secondary outcomes were the occurrence of any other
major thrombosis, major bleeding and death. All out-
comes were measured during hospitalization for COVID-
19 or assessed by the family doctor for patients managed
at home. Myocardial infarction, stroke, and peripheral
arterial thrombosis were diagnosed by objective tests
including electrocardiographic changes, cerebral CT scan,
and angiography, respectively. For the definition and
assessment of thrombotic and hemorrhagic events, the
International Statistical Classification of Diseases and
Related Health Problems 10th Revision (ICD-10)-WHO
current version16 were used.
The use of low molecular weight heparin (LMWH) as
antithrombotic prophylaxis was recorded, defining the
dose as prophylactic low-dose (4000–6000 IU sc fixed-
dose q 24 h) or therapeutic dose (100 IU/kg bw sc q 12 h).
LMWH doses higher than the prophylactic ones but not
reaching those of therapeutic level were defined as
intermediate dose.
Potential risk factors for primary and secondary end-
points were investigated, including patient comorbidities,
MPN type and status, MPN-directed therapies, laboratory
parameters at COVID-19 diagnosis, COVID-19 severity,
and treatments. Results concerning mortality rate in this
series were previously reported17.
Statistical analysis
An initial sample size of at least 80 patients was esti-
mated to detect a proportion of PE of 0.35 vs. 0.20, as
reported in non-MPN COVID-19 cases (alpha= 0.05;
beta= 0.20).
Continuous variables are expressed as median (IQR)
and the Kruskal–Wallis test was used to compare MPN
phenotypes. Categorical variables are presented as fre-
quencies and percentages, and were analyzed using the
χ² test or Fisher’s exact test, as appropriate.
Cumulative incidence function (CIF) for death, throm-
bosis, and bleeding were estimated considering death as
competing event. Univariate analysis testing the associa-
tion of each explanatory variables and thrombosis were
performed using the Mann–Whitney U test, or χ² test, or
Fisher’s exact test, as appropriate. Multivariable Fine and
Gray regression model was finally applied to find inde-
pendent predictors of thrombosis among those clinically
relevant and significantly associated in univariate analysis,
treating death as competing event.
Two-sided P-values of 0.05 or less were considered to
indicate statistical significance. All analyses were per-
formed using Stata (StataCorp, College Station, TX) sta-
tistical software, release 16.1.
Results
Description of thrombotic and major bleeding events
In Table 1, we report the frequency and types of
thrombosis and bleeding observed over a median of
50.5 days of follow-up (IQR: 16.0–69.0) in 162 patients
with MPN fulfilling eligibility criteria defined for this
analysis. During the acute phase of infection, 19 patients
experienced 22 thrombo-hemorrhagic events at home
(n= 1/40, 2.5%), or during hospitalization in regular
wards (n= 13/105, 12.4%) or in ICU (n= 5/17, 29.4%)
(p= 0.016). Overall, only three arterial thrombosis were
documented (1.9%), whereas the majority were VTE (n=
12, 7.4%), detected with a significantly higher frequency in
ET patients (n= 8/48, 16.7%) than in PV (n= 2/42, 4.8%)
or MF (n= 2/56, 3.6%) (p= 0.031). In ET, 7 of 8 VTE
(87.5%) were PE, of which one concomitant with DVT of
the legs. Two additional PE were seen in patients with PV
and MF each. All but two patients with VTE were
receiving anticoagulation with low or intermediate doses
(n= 5/10, 50%) or therapeutic doses (n= 5/10, 50%) of
LMWH. Mortality was recorded in 7 of 14 (50%) patients
with thrombosis, of which one was attributed to acute
myocardial infarction, while the other 6 were not con-
sidered to be related to the previous vascular event; causes
of death were indistinguishable from other concomitant
conditions, such as multi-organ failure (MOF) (n= 4),
pneumonia (n= 1), or unknown reason (n= 1).
Seven patients of 162 (4.3%) developed major bleeding,
in particular in MF, where all the four hemorrhagic epi-
sodes required blood transfusions. These events were
diagnosed starting from the second week after the onset of
the SARS-CoV-2 infection and occurred mainly in
patients admitted to regular ward (n= 6/7, 85.7%) and in
one case in ICU (14.3%). Details of bleeding in the seven
patients are illustrated in Table 2. We note that most of
the bleeding events occurred in patients over the age of 70
years with MF and affected the gastrointestinal tract in
three cases. All but two patients were receiving antic-
oagulant treatment: four were on LMWH (low-dose n=
3, therapeutic dose n= 1) and one was on apixaban. Only
patient #1 with MF (Table 2) had an activated partial
thromboplastin time (aPTT) prolongation and a moderate
thrombocytopenia despite the absence of heparin pro-
phylaxis. Severe thrombocytopenia < 30 × 109/L was noted
in three patients (#5, #6, and #7), two of them receiving
low-dose LMWH. All bleeding episodes but one occurred
in patients admitted to regular wards.
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Cumulative incidence of thrombosis and bleeding
Figure 1a reports CIF curves for the competing risks of
death and thrombosis. At 60 days, mortality reached
26.6% (95% CI: 4.9–13.4%). Most of the fatal events
occurred within the first 15 days (20%); of these, 7 in
patients experiencing major thrombosis (see above) and
subsequently the curve grew more slowly until 30 days,
becoming almost stable afterwards. Adjusting for the
competing risk of dying before the event, probability of
total thrombosis progressively increased in the first
month and reached 8.5% after 60 days follow. The
cumulative incidence rate at 10, 20, 30 days was 4.1%,
5.9% and 7.1%, respectively. In COVID-19 patients fol-
lowed at home or in regular ward (n= 40, 25% and n=
105, 65%, respectively), the rate was 1.0% and 2.8%,
respectively, whereas it reached 18.4% in the 17 (10% of
the entire cohort) ICU patients.
The overall major bleeding rate was 4.3% (95% CI:
1.9–8.2%) and the 7 events occurring in 7 patients
accounted for a cumulative incidence rate of 0.6%, 2.4%
and 3.6% at 10, 20, 30 days, respectively (Fig. 1b).
Fatal events were reported in 41 of 162 patients (25.3%),
and the two most frequently reported were pneumonia
(n= 15, 37%) and MOF (n= 17, 41%), being the
remaining unknown or unspecified causes (n= 9, 22%).
Note that among the 11 deaths that occurred in ET
patients, pneumonia was more frequent (n= 6, 55%) than
in PV (n= 2/6, 33%) and MF (n= 6/21, 29%) while there
was no difference between fatalities from MOF in ET
(n= 5/11, 45%) and PV (n= 3/6, 50%). Remarkably, ET
patients with thromboses vs. the ones without these
events had a survival probability of 53.6% (95% CI:
23.3–76.6%) and 75.6% (95% CI: 67.5–82.0%), respectively
(p= 0.052) (supplementary Fig. 1S).
Univariate and multivariate analysis for thrombosis
MPN patients’ characteristics stratified by thrombosis
are presented in Table 3. Gender, age and MPN type
Table 1 Types of thrombosis and bleeding, by MPN phenotypes.
Total ET PV MF Pre-PMF p-value
N= 162 N= 48 N= 42 N= 56 N= 16
Thrombosis
Pts with thrombosis, n (%) 14 (8.6%) 8 (16.7%) 2 (4.8%) 3 (5.4%) 1 (6.3%) 0.13
N thrombosis, n (%) 15 (10.0%) 9 (18.8%) 2 (4.8%) 3 (5.4%) 1 (6.3%) 0.35
Arterial, n (%) 3 (1.9%) 1 (2.1%) 0 (0.0%) 1 (1.8%) 1 (6.3%) 0.47
AMI 1 0 1 0
Stroke 1 1 0 0
PAT 1 0 0 1
Venous, n (%) 12 (7.4%) 8 (16.7%) 2 (4.8%) 2 (3.6%) 0 (0.0%) 0.031
PEa 10 6 2 2
DVT+PEa 1 1 0 0
SVT 1 1 0 0
Time to any thrombosis, days, median (IQR) 11.5 (4.0–25.0) 7.0 (2.5–11.5) 8.0 (1.0–15.0) 25.0 (16.0–32.0) 28.0 (28.0–28.0) 0.27
Time to PE, days, median (IQR) 8.0 (0.0–14.0) 4.0 (0.0–8.0) 7.0 (0.0–14.0) 27.5 (24.0–31.0) 0.097
Bleeding
Pts with bleeding, n (%) 7 (4.3%) 1 (2.1%) 2 (4.9%) 4 (7.1%) 0 (0.0%) 0.51
Sites 0.20
Gastrointestinal 3 0 0 3
Muscle 2 1 1 0
Hemoptysis 2 0 1 1
Trasfusion need, n (%) 5 (3.1%) 1 (2.1%) 0 (0.0%) 4 (7.1%) 0.030
Time to bleeding, days, median (IQR) 16.0 (13.0–24.0) 14.0 (14.0–14.0) 23.0 (16.0–30.0) 17.5 (6.5–23.0) 0.50
ET essential thrombocythemia, PV polycythemia vera, MF myelofibrosis, pre-PMF prefibrotic myelofibrosis, Pts patients, AMI acute myocardial infarction, PAT
pheripheral arterial thrombosis, PE pulmonary embolism, DVT deep vein thrombosis of the legs, SVT superficial vein thrombosis, IQR interquartile range.
aPE diagnosis confirmed by imaging n= 8, not confirmed n= 3.
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distribution were comparable in the two groups, with the
exception of a significantly higher proportion of throm-
bosis in ET patients (p= 0.018). We did not find any
correlation between driver mutations and the incidence of
thrombosis. In particular, no difference was found in
patients with or without thrombosis according to the
presence of JAK2V617F, even if stratified by MPN phe-
notypes. Of note, ET, compared to the other phenotypes
(Supplementary Table 1S), showed no difference in terms
of COVID-19 severity, as defined by age, patient managed
at home, admitted to regular ward or ICU, and inflam-
matory markers, with the exception of higher platelet
counts at COVID-19 diagnosis (p= 0.012).
Figure 1c illustrates the remarkable difference in the
CIF of thrombosis in patients with ET compared with the
other MPN phenotypes. Of note is the rapid steepness of
the curve starting from the first hours after hospitalization
and reaching the peak after 30 days.
Such variables as history of thrombosis or bleeding,
splenomegaly, duration of MPN disease, or proportion of
patients treated with cytoreductive therapy were similar in
the two groups (Table 3). Likewise, COVID-19-related
symptoms were registered with comparable frequency
and severity in the two groups, and no significant differ-
ence was detected in the frequency of comorbidities.
The two groups did not differ for blood hemoglobin
values, leukocyte, and platelet counts at COVID-19
diagnosis. However, at COVID-19 diagnosis, patients
had significantly lower (p < 0.0001) platelet number
(median 250.5 × 109/L, IQR: 151–398) than at the time of
last follow-up visit performed at median of 47 days (IQR:
28–67) before diagnosis of SARS CoV-2 infection (median
326 × 109/L, IQR: 218–477). This decline was remarkable
in ET (−23.3%; p= <0.0001) and less pronounced in PV
(−16.4%; p= 0.1730) (Fig. 2a) and was associated with
higher mortality rate (p= 0.0010), mainly due to pneu-
monia (p= 0.0051), which was reported in higher pro-
portion of ET than in PV and MF. Conversely, the platelet
drop was not linked to a significant difference of death for
MOF (p= 0.06) (Fig. 2b).
Levels of inflammation markers (neutrophil/lymphocyte
ratio (NLR), platelet/lymphocyte ratio (PLR) and C-
reactive protein (CRP)) were significantly higher in
patients with thrombosis (p= 0.004, 0.02, 0.019, respec-
tively). Concerning blood coagulation tests, aPTT, pro-
thrombin time (PT), and fibrinogen values were within the
normal values, while a non-significant trend for D-Dimer
increase was seen in cases with thrombosis (p= 0.10).
However, in patients with ET and thrombosis, the levels
were significantly higher (median 4675.0 ng/mL, IQR:
2590.0–10,000.0) compared to cases without thrombosis
(median: 367.0 ng/mL, IQR: 200.0–884.0; p < 0.0001).
The effects of COVID-19 severity in patients with
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evidenced by the significant association with the need for
hospitalization in the ICU, the elevated systemic inflam-
matory status (NLR) and the more frequent prescription
of corticosteroids. The final multivariate Fine and Gray’s
regression model showed that risk factors independently
associated with thrombosis were transfered to ICU (sub-
distribution hazard ratio [SHR]= 3.73, 95% CI=
1.14–12.23, p= 0.029), NLR (SHR= 1.16, 95% CI=
1.06–1.27, p= 0.001) and ET phenotype (SHR= 4.37,
95% CI= 1.51–12.64, p= 0.006), the latter being the
factor with the highest SHR.
Discussion
The primary goal of this retrospective observational
study was to evaluate the rate and risk factors for
thrombosis and bleeding in patients with MPN and
COVID-19, collected in Europe during the first wave of
pandemic, from 15 February to 30 June 2020.
Rate of thrombosis and bleeding
Overall, the cumulative rate of arterial and VTE events
was 8.6%, occurring in 14 out of 162 MPN patients during
60 days of observation for COVID-19. Most of the events
during SARS-CoV-2 infection were VTE, as already
reported18,19, indicating that their occurrence was more
closely linked to infection rather than MPN, in which
events are more commonly represented by arterial
thrombosis10–12. These complications occurred in all
patients but one, despite LMWH prophylaxis. In this
regard, it is relevant to note that prescription of antith-
rombotic prophylaxis in COVID-19 patients, either
managed at home or in regular wards during the first
months of pandemic, was not considered a standard
therapy, and this may explain why only 57% of MPN cases
received antithrombotic prophylaxis which, in almost all
patients, was LMWH. The dosage of this drug was het-
erogeneous (in 80% of patients was low-intermediate and
in 20% therapeutic), mirroring the clinical practice in
non-MPN patients with COVID-1920. The Scientific and
Standardization Committee of the International Society
on Thrombosis and Hemostasis (ISTH) has suggested a
universal strategy of routine thromboprophylaxis with
LMWH after a careful assessment of the bleeding risk21.
However, there is a lack of studies documenting which
dose of LMWH has a most favorable risk/efficacy profile;
therefore, in the current clinical practice, the dose is
chosen on an empirical basis, evaluating the underlying
pathology concomitant with COVID19 and the presence
of generic vascular risk factors21.
In patients with PV and MF, the rate of VTE was 4.8%
and 5.4%, respectively, overall similar to that reported in
non-MPN acutely ill medical patients with COVID-19
Fig. 1 Cumulative incidence of thrombosis and bleeding. Cumulative Incidence Function (CIF) of thrombosis overall (A) and by MPN phenotypes
(C), and bleeding (B), considering death as competing event.
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Table 3 Univariate analysis for thrombosis.
Total No thrombosis Thrombosis p-value
N= 162 N= 148 N= 14
Sex, n (%) 1.00
Female 66 (40.7%) 60 (40.5%) 6 (42.9%)
Male 96 (59.3%) 88 (59.5%) 8 (57.1%)
Age (years), median (IQR) 70.6 (60.0–79.9) 70.6 (60.0–79.9) 70.6 (60.0–80.0) 0.91
<60 years, n (%) 40 (24.8%) 37 (25.2%) 3 (21.4%) 1.00
60–70 years, n (%) 36 (22.4%) 33 (22.4%) 3 (21.4%)
>70 years, n (%) 85 (52.8%) 77 (52.4%) 8 (57.1%)
MPN diagnosis, n (%) 0.17
ET 48 (29.6%) 40 (27.0%) 8 (57.1%) 0.018
PV 42 (25.9%) 40 (27.0%) 2 (14.3%) 0.30
MF 56 (34.6%) 53 (35.8%) 3 (21.4%) 0.28
Pre-PMF 16 (9.9%) 15 (10.1%) 1 (7.1%) 0.72
JAK2V617F, n (%) 112 (70.9%) 103 (71.5%) 9 (64.3%) 0.57
CALR, n (%) 26 (29.5%) 23 (28.7%) 3 (37.5%) 0.61
MPL, n (%) 5 (6.0%) 4 (5.2%) 1 (16.7%) 0.26
Previous thrombosis, n (%) 23 (14.4%) 20 (13.7%) 3 (21.4%) 0.43
Previous bleeding, n (%) 12 (7.5%) 12 (8.2%) 0 (0.0%) 0.26
MPN duration before COVID-19 onset (years), median (IQR) 5.9 (2.9–10.8) 5.9 (2.6–10.4) 5.9 (4.1–10.9) 0.60
Blood values before COVID-19 diagnosisa, median (IQR)
Hemoglobin, g/dL 13.0 (11.4–14.2) 12.9 (11.3–14.3) 13.1 (12.2–14.0) 0.77
White blood cells, ×109/L 7.2 (5.4–10.3) 7.2 (5.5–10.1) 6.5 (5.2–12.5) 0.66
Platelets, ×109/L 326.0 (218.0–477.0) 320.0 (214.5–466.0) 369.5 (288.0–550.0) 0.29
MPN-directed therapy before COVID-19 diagnosisa, n (%)
Hydroxyurea 73 (45.1%) 66 (44.6%) 7 (50.0%) 0.70
Discontinued after COVID-19b 9/46 (20%) 7/39 (18%) 2/7 (28%) 0.61
Ruxolitinib 40 (24.7%) 37 (25.0%) 3 (21.4%) 0.77
Discontinued after COVID-19 9/40 (23%) 8/37 (22%) 1/3 (33%) 0.55
Anagrelide 8 (4.9%) 6 (4.1%) 2 (14.3%) 0.091
Interferon 4 (2.5%) 4 (2.7%) 0 (0.0%) 0.53
Other cytoreductive drugs 5 (3.1%) 5 (3.4%) 0 (0.0%) 0.48
ASA 94 (58.0%) 83 (56.1%) 11 (78.6%) 0.10
Patient disposition, n (%) 0.010
Home 40 (24.8%) 39 (26.5%) 1 (7.1%)
Regular ward 104 (64.6%) 96 (65.3%) 8 (57.1%)
ICU 17 (10.6%) 12 (8.2%) 5 (35.7%)
Main symptoms, n (%)
Fever 130 (80.2%) 118 (79.7%) 12 (85.7%) 0.59
Dispnea 89 (54.9%) 79 (53.4%) 10 (71.4%) 0.19
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Table 3 continued
Total No thrombosis Thrombosis p-value
N= 162 N= 148 N= 14
Gastrointestinal 19 (11.7%) 19 (12.8%) 0 (0.0%) 0.15
Comorbidities, n (%)
Cerebrovascular disease 21 (13.0%) 19 (12.9%) 2 (14.3%) 0.89
Chronic dialysis/Kidney disease 15 (9.3%) 14 (9.5%) 1 (7.1%) 0.77
Chronic heart failure 22 (13.8%) 20 (13.6%) 2 (15.4%) 0.86
COPD 22 (13.7%) 20 (13.6%) 2 (14.3%) 0.94
Current/former tobacco smoker 33 (23.2%) 31 (24.2%) 2 (14.3%) 0.40
Hyperlipidemia 45 (29.0%) 41 (28.9%) 4 (30.8%) 0.89
Hypertension 97 (61.4%) 91 (63.2%) 6 (42.9%) 0.14
Antihypertensives use 93 (60.8%) 89 (64.0%) 4 (28.6%) 0.010
ACE inhibitors/ARBs 54 (36.7%) 53 (39.6%) 1 (7.7%) 0.023
Other 33 (21.6%) 31 (22.3%) 2 (14.3%) 0.49
Diabetes mellitus 19 (11.9%) 18 (12.3%) 1 (7.7%) 0.62
O2 saturation (%), median (IQR) 93.0 (88.0–96.0) 93.0 (88.0–96.0) 94.0 (90.0–96.0) 0.81
COVID-19-directed drugs, n (%)
Steroid 41 (27.2%) 34 (24.8%) 7 (50.0%) 0.044
Antibiotic 104 (68.9%) 91 (66.4%) 13 (92.9%) 0.042
Hydroxychloroquine 93 (59.6%) 84 (59.2%) 9 (64.3%) 0.71
Antiviral 54 (35.1%) 48 (34.3%) 6 (42.9%) 0.52
Lopinavir/Ritonavir 44 (88.0%) 38 (86.4%) 6 (100.0%) 1.00
Other 6 (12.0%) 6 (13.6%) 0 (0.0%)
Experimental 17 (10.7%) 14 (9.7%) 3 (21.4%) 0.17
Tocilizumab 13 (76.5%) 10 (71.4%) 3 (100.0%) 1.00
Ruxolitinib 2 (11.8%) 2 (14.3%) 0 (0.0%)
Other 2 (11.8%) 2 (14.3%) 0 (0.0%)
Antithrombotic 88 (56.8%) 76 (53.9%) 12 (85.7%) 0.022
LMWH 84 (54.2%) 72 (51.1%) 12 (85.7%) 0.013
Low-intermediate dose 62 (79.5%) 56 (74.8%) 6 (50.0%) 0.34
Therapeutic dose 16 (20.5%) 10 (15.2%) 6 (50.0%)
Laboratory parameters at COVID-19 diagnosis, median (IQR)
Hemoglobin, g/dL 12.4 (10.0–13.5) 12.3 (9.9–13.5) 12.9 (11.4–13.8) 0.37
White blood cells, ×109/L 6.6 (4.7–10.3) 6.5 (4.6–10.3) 7.4 (5.4–11.3) 0.35
Lymphocytes, ×109/L 0.9 (0.6–1.6) 0.9 (0.6–1.6) 0.6 (0.4–0.9) 0.049
Neutrophils, ×109/L 4.8 (3.2–7.8) 4.7 (3.1–7.6) 4.9 (4.3–7.8) 0.61
Monocytes, ×109/L 0.4 (0.3–0.7) 0.4 (0.3–0.7) 0.4 (0.2–0.6) 0.45
Eosinophils, ×109/L 0.0 (0.0–0.1) 0.0 (0.0–0.1) 0.0 (0.0–0.1) 0.24
Basophils, ×109/L 0.0 (0.0–0.1) 0.0 (0.0–0.1) 0.0 (0.0–0.0) 0.58
Platelets, ×109/L 250.5 (151.0–397.5) 248.5 (152.0–375.0) 347.0 (74.0–408.0) 0.93
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Table 3 continued
Total No thrombosis Thrombosis p-value
N= 162 N= 148 N= 14
Neutrophils/lymphocytes ratio 5.2 (3.4–9.0) 4.9 (3.4–8.1) 10.5 (6.9–13.4) 0.004
Platelets/lymphocytes ratio 292.1 (172.3–450.0) 284.5 (157.6–395.2) 485.5 (286.1–678.2) 0.027
C-reactive protein, mg/dL 73.8 (23.0–156.8) 72.5 (18.8–134.1) 168.7 (81.4–219.0) 0.019
Fibrinogen, mg/dL 473.0 (276.5–598.5) 469.0 (270.0–597.0) 500.0 (400.0–689.0) 0.62
D-Dimer, ng/mL 660.0 (282.0–1655.0) 622.0 (280.5–1477.0) 2000.0 (642.0–4675.0) 0.100
INR 1.2 (1.0–1.3) 1.2 (1.0–1.3) 1.2 (1.1–1.2) 0.46
MPN myeloproliferative neoplasms, ET essential thrombocythemia, PV polycythemia vera, MF myelofibrosis, pre-PMF prefibrotic myelofibrosis, ASA acetylsalicylic acid,
ICU intensive care unit, COPD chronic obstructive pulmonary disease, ACE angiotensin-converting-enzyme, ARBs angiotensin II receptor blockers, O2 oxygen, LMWH
low molecular weight heparin, INR international normalized ratio, IQR interquartile range.
aData refer to the last follow-up of MPN control before COVID-19 diagnosis, performed at a median of 47 days earlier (IQR: 28–67).
bData available for 46 of 73 patients treated with Hydroxyurea.
Fig. 2 Platelet changes at COVID-19. Median platelet counts before and at COVID-19 diagnosis, by MPN phenotype (A) and by causes of death (B).
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admitted in regular wards6. Conversely, the rate of
thrombosis was higher in ET, even though the indicators
of COVID-19 severity did not show differences compared
with the other MPNs. In these patients, vascular events
happened shortly after admission to hospital as docu-
mented by the steepness of the cumulative incidence
curve that reached 16.7% after 30 days of observation.
This incidence is higher than that reported in most series
of non-MPN patients with COVID-19 admitted in regular
ward6. We point out that the higher frequency of VTE, in
comparison with arterial thrombosis, is a finding strictly
linked to the infection and contrasts with the experience
outside COVID-19 settings, in which the opposite is the
rule10–12. Remarkably, these events had a notable impact
on survival of these patients that was around 25% inferior
than in ET patients without thrombosis.
As expected, patients transferred to ICU (n= 17/162;
10.6%) experienced a significantly higher incidence of
thrombosis than those requiring non-invasive respiratory
support and admitted in regular wards (p= 0.004).
Unfortunately, we could not confirm the relationship
between D-Dimer elevation and VTE6,22, likely due to the
limited number of tests carried out in most of these
patients; only a trend for this association was shown (p=
0.10). However, in ET patients with VTE, the D-Dimer
values were significantly higher than in the ones without
thrombosis (p < 0.0001).
While the peak of thrombotic events occurred in the
first days after COVID-19 diagnosis, bleeding episodes
were reported later, starting 2 weeks afterwards, and
accounted for a cumulative rate of 5%, a figure higher than
2.3% reported in the non-ICU general population with
COVID-1923. We underscore the severity of these events,
requiring blood transfusion particularly in MF. In 4 of our
cases, a coagulopathy or severe thrombocytopenia were
associated with severe bleeding suggesting caution on the
empiric intensification of LMWH particularly in MF.
Risk factors
The low number of bleeding events precluded an analysis
of risk factors and also in multivariate models for throm-
bosis, few confounders could be included given that only
14 events were ascertained. As expected, patient transfer to
ICU and NLR inflammatory marker were confirmed sig-
nificant factors associated with total thrombosis.
Of great interest is the association between ET and
thrombosis, regardless of inflammation indicators and the
severity of COVID-19. This finding requires further
confirmation in a larger series of patients; however, it
highlights the role of platelets in the thrombogenesis of
MPN patients with COVID-19. During the acute phase of
infection, our patients had platelet count higher than the
other MPN but significantly lower than the value col-
lected in the last follow-up before the infection, possibly
indicating a platelet consumption due to low grade dis-
seminated coagulation24. This process might be related to
the systemic endothelial vascular cell damage associated
with viral infection4,5 and involve the interaction of pla-
telets, leukocytes, neutrophil extracellular trap (NET)
formation25, and vascular endothelium, leading to classic
arterial and venous thrombosis, but also to lung and other
tissues vessel occlusion and hypoxia1,2. We can speculate
that in at least some of the MPN patients who died for
sudden respiratory deterioration, the decline of platelet
number associated with the initial diagnosis of pneumonia
might be due to pulmonary thrombosis, in the context of
a “local” intravascular coagulation and complement26.
Limitations and conclusion
The main limitations of this observational study are
related to its retrospective design and to the limited
number of patients. However, this constrain can hardly be
avoided when dealing with both a rare condition, such as
MPNs, and an exceptional situation of emergency, such as
the COVID-19 crisis.
In conclusion, our study should be considered as an
exploratory analysis whose results pave the way for larger
follow-up studies hopefully not having the same limita-
tions. In particular, the enhanced susceptibility to ET-
associated thrombosis is a finding that needs to be delved,
especially for the possibility to tailor antiplatelet and/or
antithrombotic drugs in SARS CoV-2-infected patients
who develop COVID-19.
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